A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden

Authors

  • Jenny Andersson From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Barbro Linderholm From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Gudrun Greim From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Birgitta Lindh From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Henrik Lindman From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Jan Tennvall From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Lena Tennvall-Nittby From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Dagny Pettersson-Sköld From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Asgerdur Sverrisdottir From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Martin Söderberg From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Sigrid Klaar From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden
  • Jonas Bergh From the Radiumhemmet, Karolinska Institute and Hospital, Stockholm (J. Andersson, B. Linderholm, S. Klaar, J. Bergh), Department of Oncology, Bora s Hospital, Boras (G. Greim), Department of Oncology, University Hospital, Umea (B. Lindh), Department of Oncology, Akademiska Hospital, Uppsala (H. Lindman), Department of Oncology, University Hospital, Lund (J. Tennvall), Department of Oncology, University, Hospital Malmo (L. Tennvall-Nittby), The Oncology Unit at Danderyds Hospital, Radiumhemet, Karolinska Hospital, Stockholm (D. PetterssonSko ld), Department of Oncology, Huddinge University Hospital, Stockholm (A. Sverrisdottir), Department of Oncology, Central Hospital, Karlstad (M. So derberg), Sweden

DOI:

https://doi.org/10.1080/02841860260088827

Abstract

Several studies have presented data on the efficacy and tolerability of trastuzumab within clinical trials. As a minority of patients is included in these trials, we undertook this retrospective study to describe trastuzumab therapy in clinical routine and its tolerability. We reviewed the medical records of the first 48 patients in Sweden who received treatment with trastuzumab on a named patient basis with (n =29) and without (n =19) chemotherapy. Forty-six patients had metastatic disease and had failed to respond to several prior regimens before starting antibody treatment. Two patients had locally advanced breast cancer failing on given neoadjuvant therapy. Patients with breast cancers with strong (3 +) c-erbB-2 overexpression tended to have an improved survival from start of trastuzumab treatment versus those with a moderate (2 +) overexpression (p =0.09). Adverse events were registered in 22 patients (46%). The most common and acute side effects were fever and chills (7 patients, 15%). The toxicity seemed reasonable but two patients (4%) suffered serious cardiac events, both of them having received previous treatment with antracyclines.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

Andersson, J., Linderholm, B., Greim, G., Lindh, B., Lindman, H., Tennvall, J., … Bergh, J. (2002). A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden. Acta Oncologica, 41(3), 276–281. https://doi.org/10.1080/02841860260088827

Issue

Vol. 41 No. 3 (2002): Acta Oncologica

Section

Articles